Our results are in line with a recent network meta-analysis including 764 trials and 421,346 patients [25] which demonstrated that use of GLP-1RA reduces all cause and cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and kidney failure, with a substantial benefit on non-fatal stroke over SGLT-2 inhibitors and notable differences in the tolerability profile. This evidence concerns the gene SLC5A2 and Stroke.